Replimune Interest Income vs Non Operating Income Net Other Analysis
REPL Stock | USD 13.26 1.67 11.19% |
Replimune financial indicator trend analysis is much more than just breaking down Replimune Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Replimune Group is a good investment. Please check the relationship between Replimune Interest Income and its Non Operating Income Net Other accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Interest Income vs Non Operating Income Net Other
Interest Income vs Non Operating Income Net Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Replimune Group Interest Income account and Non Operating Income Net Other. At this time, the significance of the direction appears to have no relationship.
The correlation between Replimune's Interest Income and Non Operating Income Net Other is 0.01. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Replimune Group, assuming nothing else is changed. The correlation between historical values of Replimune's Interest Income and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Replimune Group are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Interest Income i.e., Replimune's Interest Income and Non Operating Income Net Other go up and down completely randomly.
Correlation Coefficient | 0.01 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Non Operating Income Net Other
Most indicators from Replimune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Replimune Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, Replimune's Selling General Administrative is quite stable compared to the past year. Enterprise Value is expected to rise to about 527.2 M this year, although the value of Tax Provision will most likely fall to about 255.2 K.
2023 | 2024 (projected) | Depreciation And Amortization | 2.7M | 2.0M | Interest Income | 580.8K | 935.8K |
Replimune fundamental ratios Correlations
Click cells to compare fundamentals
Replimune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Replimune fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 234.1M | 543.1M | 461.2M | 646.6M | 487.7M | 359.6M | |
Other Current Liab | 303K | 5.3M | 9.8M | 24.7M | 30.1M | 31.6M | |
Total Current Liabilities | 11.9M | 14.5M | 20.8M | 33.8M | 40.4M | 42.5M | |
Total Stockholder Equity | 183.7M | 498.7M | 411.2M | 555.3M | 374.5M | 291.7M | |
Net Tangible Assets | 137.9M | 183.7M | 498.7M | 411.2M | 472.9M | 496.6M | |
Property Plant And Equipment Net | 58.2M | 57.7M | 55.6M | 52.4M | 52.4M | 39.7M | |
Net Debt | (17.7M) | (149.2M) | (73.1M) | (85.8M) | 1.4M | 1.5M | |
Retained Earnings | (112.3M) | (193.2M) | (311.2M) | (485.5M) | (701.3M) | (666.2M) | |
Accounts Payable | 3.4M | 2.4M | 3.7M | 5.4M | 2.6M | 3.7M | |
Cash | 59.5M | 182.5M | 105.9M | 146.6M | 74.5M | 87.0M | |
Non Current Assets Total | 59.8M | 59.4M | 57.2M | 54.0M | 54.1M | 41.1M | |
Cash And Short Term Investments | 168.6M | 476.3M | 395.7M | 583.4M | 420.7M | 311.0M | |
Net Receivables | 3.0M | 3.0M | 3.1M | 2.9M | 4.9M | 3.2M | |
Common Stock Total Equity | 24K | 32K | 37K | 47K | 54.1K | 31.9K | |
Common Stock Shares Outstanding | 34.3M | 46.2M | 52.2M | 58.2M | 66.6M | 47.1M | |
Short Term Investments | 109.1M | 293.8M | 289.7M | 436.8M | 346.2M | 223.9M | |
Liabilities And Stockholders Equity | 234.1M | 543.1M | 461.2M | 646.6M | 487.7M | 359.6M | |
Non Current Liabilities Total | 38.5M | 29.8M | 29.2M | 57.5M | 72.8M | 48.8M | |
Capital Surpluse | 1.1M | 198.6M | 297.0M | 692.2M | 796.1M | 835.9M | |
Other Current Assets | 2.7M | 4.5M | 3.3M | 6.3M | 8.1M | 4.1M | |
Other Stockholder Equity | 297.0M | 692.2M | 723.4M | 1.0B | 1.1B | 552.5M | |
Total Liab | 50.4M | 44.4M | 50.0M | 91.3M | 113.2M | 67.8M | |
Property Plant And Equipment Gross | 58.2M | 57.7M | 60.4M | 59.6M | 62.3M | 42.8M | |
Total Current Assets | 174.3M | 483.7M | 404.0M | 592.6M | 433.7M | 318.5M | |
Accumulated Other Comprehensive Income | (982K) | (394K) | (973K) | 5.7M | 4.9M | 5.1M | |
Common Stock | 32K | 37K | 47K | 57K | 61K | 40.0K | |
Property Plant Equipment | 12.2M | 58.2M | 7.4M | 55.6M | 63.9M | 67.1M | |
Net Invested Capital | 193.5M | 498.7M | 411.2M | 583.9M | 419.3M | 362.1M | |
Net Working Capital | 162.4M | 469.2M | 383.2M | 558.8M | 393.2M | 339.0M | |
Short Long Term Debt Total | 41.8M | 33.3M | 32.8M | 60.8M | 75.9M | 46.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.